March 24, 2010 (FinancialWire) — Myriad Genetics, Inc. (NASDAQ: MYGN) provided further clinical validation supporting the company’s newest molecular diagnostic product, PROLARIS, presenting data for a well-described cohort of patients for which 10-year follow-up data were available following prostatectomy surgery, which showed that PROLARIS is a significant predictor of prostate cancer recurrence in training and validation cohorts.

Other recent FinancialWire(tm) news items pertaining to the oncology and stem cell sectors today include Cell Therapeutics, Inc. (NASDAQ: CTIC) go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+CTIC%29%22), BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+BPAX%29%22), Myriad Genetics, Inc. (NASDAQ: MYGN) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+MYGN%29%22), Nektar Therapeutics (NASDAQ: NKTR) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+NKTR%29%22), Genomic Health, Inc. (NASDAQ: GHDX) (go to http://www.financialwire.net/?s=%22%28NASDAQ%3A+GHDX%29%22), Entest BioMedical, Inc. (OTCBB: ENTB) (go to http://www.financialwire.net/?s=%22%28OTCBB%3A+ENTB%29%22), and others.

Source: Zangani Investor Community (http://www.investrend.com/about/zangani).

FinancialWire(tm) is committed to serving the financial community through true journalism and providing relevant resources to investors. Standards-based, independent equity research on numerous public companies is available through the Investrend Research Syndicate (http://www.investrend.com/reports) written by FIRST Research Consortium (http://www.investrend.com/FIRST) member-providers. Free annual reports and company filings for companies mentioned in the news are available through the Investrend Information Syndicate (at http://investrend.ar.wilink.com/?level=279). FinancialWire(tm), in cooperation with the Investrend Broadcast Syndicate, also provides complete, daily conference call and webcast schedules as a service to shareholders and investors via the FirstAlert(tm) Network’s “FirstAlert(tm) Daily” (http://www.financialwire.net/news-alerts/).

FinancialWire(tm) is a fully independent, proprietary news wire service. FinancialWire(tm) is not a press release service, and receives no compensation for its news, opinions or distributions. Further disclosure is at the FinancialWire(tm) website(http://www.financialwire.net/disclosures.php). Contact FinancialWire(tm) directly via inquiries@financialwire.net.

Source of original content for this article: (http://www.zangani.com/node/4024).

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.